Crown Bioscience expands US operations
Company establishes Center of Excellence for Oncology in San Diego
Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has expanded its San Diego facility to create a US Centre of Excellence for Oncology to support increasing demand for oncology research studies.
The enlarged 22,000ft2 facility more than triples CrownBio’s original capacity at this site, adding multiple holding rooms and dedicated procedure and formulation space.
The USDA-certified facilities, fitted with Biosafety Level 2 environmental controls, also allow viral agents for oncolytic virus studies to be used.
‘By expanding our US Centre of Excellence for Oncology, we have enhanced both our capabilities and capacity to meet the increased demand for the types of oncology research critical to public health,’ said Jean-Pierre Wery, CEO of CrownBio.
This expansion enables scientists to isolate and compartmentalise incoming projects, including separate suites for work with infectious agents. CrownBio’s immuno-oncology capabilities will be enlarged, with separate rooms dedicated to immunocompetent and immunodeficient models. It also improves CrownBio’s ability to minimise contamination risk while protecting data integrity of the study.
‘This expanded San Diego facility will enable CrownBio to continue to offer our clients the timelines and responsiveness they demand and, at the same time, allow us to optimise resource and capacity management in the US,' said Mike Prosser, CrownBio’s General Manager of European and North American operations. ‘By creating a single Center of Excellence in North America, we can now deliver the highest quality research from a truly state-of-the art facility.’
